ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
205.065
-0.225
( -0.11% )
Updated: 13:33:01

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
205.065
Bid
-
Ask
-
Volume
162,183
202.81 Day's Range 208.14
180.93 52 Week Range 348.67
Market Cap
Previous Close
205.29
Open
207.08
Last Trade
1
@
205.0618
Last Trade Time
13:33:13
Financial Volume
$ 33,314,401
VWAP
205.4124
Average Volume (3m)
364,974
Shares Outstanding
38,703,659
Dividend Yield
-
PE Ratio
87.00
Earnings Per Share (EPS)
2.35
Revenue
1.06B
Net Profit
90.95M

About Penumbra Inc

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurova... Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for the neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Dover, Delaware, USA
Founded
1970
Penumbra Inc is listed in the Surgical,med Instr,apparatus sector of the New York Stock Exchange with ticker PEN. The last closing price for Penumbra was $205.29. Over the last year, Penumbra shares have traded in a share price range of $ 180.93 to $ 348.67.

Penumbra currently has 38,703,659 shares outstanding. The market capitalization of Penumbra is $7.91 billion. Penumbra has a price to earnings ratio (PE ratio) of 87.00.

Penumbra (PEN) Options Flow Summary

Overall Flow

Bullish

Net Premium

26k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

PEN Latest News

Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference

Penumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference PR Newswire ALAMEDA, Calif., May 1, 2024 ALAMEDA, Calif., May 1, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN...

Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots

Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots PR Newswire ALAMEDA, Calif., April 23, 2024 Lightning Flash™ 2.0 features advanced computer...

Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024

Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024 PR Newswire ALAMEDA, Calif., April 9, 2024 ALAMEDA, Calif., April 9, 2024 /PRNewswire/...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.560.766565932041203.505208.7799196.23351941202.99275514CS
4-10.975-5.08007776338216.04226.27196.23310733209.57213684CS
12-57.545-21.9127222878262.61277.34196.23364974229.97033365CS
268.7754.4704264099196.29277.34180.93371114229.64764514CS
52-79.935-28.0473684211285348.67180.93376081254.29736981CS
156-101.255-33.0553016453306.32348.67114.865310757229.95499521CS
26077.75561.0753279397127.31348.67107.5360253210.54514455CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUVOHoldco Nuvo Group DG Ltd
 5.0741
(2,206.41%)
51.68k
NUWENewellis Inc
$ 0.195
(46.62%)
35.42M
XBPXBP Europe Holdings Inc
$ 1.9171
(46.34%)
14.42M
ENVXEnovix Corporation
$ 9.24
(41.94%)
16.07M
SGBXSafe and Green Holdings Corporation
$ 2.99
(35.66%)
14.71M
XPELXPEL Inc
$ 35.91
(-33.24%)
1.19M
BONBon Natural Life Ltd
$ 2.62
(-31.95%)
692.42k
ARAYAccuray Incorporated
$ 1.55
(-28.57%)
3.41M
PLTNPlutoniam Acquisition Corporation
$ 6.5717
(-28.18%)
71.68k
BNAIBrand Engagement Network Inc
$ 1.5484
(-26.62%)
334.31k
JAGXJaguar Health Inc
$ 0.287514
(27.78%)
116.85M
SQQQProShares UltraPro Short QQQ
$ 11.9109
(-2.53%)
91.49M
ALLRAllarity Therapeutics Inc
$ 1.3401
(-2.18%)
85.38M
FFIEFaraday Future Intelligent Electric Inc
$ 0.04215
(-8.57%)
78.84M
TSLATesla Inc
$ 180.0209
(0.02%)
63.58M

PEN Discussion

View Posts
@LaughinPaulRyan @LaughinPaulRyan 3 years ago
... ALL NEWS IS GOOD? ... $PEN



CNBC's Scott Wapner reports on why Quintessential Capital Management is shorting Penumbra and why it's questioning the safety of its medical devices.

👍️0
@LaughinPaulRyan @LaughinPaulRyan 3 years ago
QCM legal team filed detailed reports with allegations of misconduct with FDA, SEC and other institutions urging thorough investigation
Deceptive behavior would point to lack of integrity unworthy of management leading $10bn healthcare company and may explain Jet7 crisis leading to multiple deaths, injuries
QCM calls on Adam Elsesser, Arani Bose to resign at once if allegations confirmed
Situation constitutes existential threat to Penumbra’s viability as a public company
👍️0
@LaughinPaulRyan @LaughinPaulRyan 3 years ago
Executive Summary

Large portion of scientific literature produced by Penumbra appears authored by fake character in sophisticated, multi-year deception
Fake character seems fabricated by Penumbra’s management attempting to hide involvement in research with significant undisclosed conflicts of interest
Conflicted research used extensively to market products to healthcare providers, to support FDA applications and to promote stock in IPO
Legal advisers: behavior, if confirmed, may constitute serious fraud threatening revocation of FDA clearances, SEC enforcement and litigation from clients
👍️0
davidsson10 davidsson10 3 years ago
https://www.qcmfunds.com/penumbra-and-its-killer-catheter/?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link
👍️0
@LaughinPaulRyan @LaughinPaulRyan 3 years ago
... ROFLMFAO ... $PEN

Penumbra Inc
Penumbra, Inc. designs, develops, manufactures, and markets medical devices. The Company offers peripheral vascular and neurovascular devices that help patients suffering from stroke and other neurovascular diseases. Penumbra operates in the United States.
CURRENT PRICE

PEN:US197.48USD-26.54-11.85%AS OF 10:55 AM EST 12/08/2020
👍️0
TREND1 TREND1 9 years ago
IPO INFO

http://www.marketwatch.com/tools/ipo-calendar
👍️0
TREND1 TREND1 9 years ago
IPO NOW HAS SYMBOL
Penumbra PEN
👍️0
TREND1 TREND1 9 years ago
IPO should be out soon.
no symbol yet.
👍️0

Your Recent History

Delayed Upgrade Clock